October 29, 2020 -- Thermo Fisher Scientific has expanded its collaboration with Symphogen to support that company's efforts to provide therapeutic proteins for biopharmaceutical discovery and development.
The initial partnership between the two firms was established in 2018. Since then, Symphogen has been using Thermo Fisher's Thermo Scientific Q Exactive Plus Orbitrap liquid chromatography-tandem mass spectrometry system with BioPharma, as well as Thermo Fisher's Thermo Scientific Orbitrap Exploris 480 mass spectrometer to develop and test therapeutic monoclonal antibody drugs.
Symphogen also uses Thermo Fisher's Thermo Scientific Orbitrap Fusion Tribrid mass spectrometer and its Vanquish ultrahigh-performance liquid chromatography systems and its Chromeleon chromatography data system software, Thermo Fisher Scientific said.